Metabolon and DIAN Open New Metabolomics Laboratory in China

RESEARCH TRIANGLE PARK, N.C. — March 27, 2018 — Metabolon, Inc., the global leader in metabolomics, announced today that its joint metabolomics laboratory with Zhejiang Dian Diagnostics Co., Ltd. (“DIAN”), one of China’s largest chains of independent medical laboratories, has achieved full validation in running Metabolon’s proprietary metabolomics platform. The joint laboratory is located in Hangzhou and has started processing client samples under an exclusive licensing agreement with Metabolon announced in February 2017. Hangzhou Calibra Diagnostics Co., Ltd. (“Calibra”), a majority-owned subsidiary of DIAN, will be the exclusive partner for providing Metabolon’s metabolomics services and commercializing its technology in China.

“Launching our global metabolomics platform in China allows us to better serve current and future customers in this significant, growing market,” said Metabolon CEO John Ryals, PhD. “Calibra has done an outstanding job establishing the laboratory, validating the platform and preparing its marketing team for this day. We look forward to a successful relationship as they expand our service offerings for research applications in clinical research, health management, traditional Chinese medicine, pharmaceuticals, consumer goods and agriculture, as well as supporting large-cohort population studies throughout the Chinese market.

“Calibra is pleased to exclusively offer Metabolon’s technology in China, and I am confident that our collaboration is going to open many new opportunities to help advance metabolomics applications in this market,” said Hua-fen Liu, Calibra CEO.

Metabolon’s technology screens the largest, most diverse metabolite reference library in the industry and leverages proprietary software and biochemistry expertise to deliver the most accurate and comprehensive metabolomics data. This data can be used by life sciences researchers to gain actionable biological insight and understand genomic and other -omics data.

About Calibra
Hangzhou Calibra Diagnostics is a subsidiary company of DIAN Diagnostics, a leading clinical diagnostic total solution provider in China. Calibra focuses on the application and product development of a variety of mass spectrometry technology platforms in life sciences, environmental sciences, and other fields. Calibra currently has four central laboratories and leverages DIAN’s diagnostic network across the country, providing a total solution including service and product development for clinical diagnostics, metabolomics research, Pharma CRO, and forensic toxicology testing.

Cautionary Note about Forward-Looking Statements
The materials provided herein that are not historical facts are or might constitute projections and other forward-looking statements regarding future events that involve substantial risks, uncertainties and assumptions. If any of these risks or uncertainties materialize, or if any of these assumptions prove to be incorrect, Metabolon’s results could differ materially from the results expressed or implied by any forward-looking statements. The risks, uncertainties and assumptions referred to above include, but are not limited to: the uncertainties inherent in biochemical research and development; decisions by regulatory authorities regarding whether and when to approve diagnostic tests; the clinical utility of Metabolon’s metabolomic services; Metabolon’s and its distributors’ ability to successfully commercialize and market both new and existing products; governmental laws and regulations affecting health care, including access, pricing and reimbursement of diagnostic tests; the strength of Metabolon’s intellectual property portfolio; Metabolon’s history of operating losses; whether Metabolon is able to achieve or sustain profitability; its highly competitive industry; its ability to compete effectively; security and privacy risks; and Metabolon’s ability to continue to innovate and provide products and services that are useful to its clients, among other risks, uncertainties and assumptions.